Teva Pharmaceutical Industries Ltd. reported on Monday that a phase II trial of its experimental Huntington's disease (HD) drug pridopidine showed a statistically significant impact on disease progression at 52 weeks vs. placebo.
"An unusually high placebo effect," however, limited investigators' ability to determine the drug's impact on motor symptoms of the disease. Despite that, Teva said that evidence of symptomatic impact was seen in stage 1 HD patients, with improvement in Total Motor Score and dystonia observed at 26 and 52 weeks in the subgroup.
The randomized, parallel-group, double-blind and placebo-controlled study, PRIDE-HD, was initiated in April 2014. It enrolled 400 patients in collaboration with